TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39288943

Group type: EXPERIMENTAL
Intervention: MESA intervention (2-session online intervention with ART information and personalized feedback + ART standard of care)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: MESA intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: SH control (information on healthy eating and physical activity + ART standard of care)
Number of subjects: 152
Study: 39289010

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 18
Study: 39289023

Group type: EXPERIMENTAL
Intervention: Artificial intelligence module with wound monitoring platform plus standard postoperative wound care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard postoperative wound care only
Number of subjects: 120
Study: 39289024

Group type: EXPERIMENTAL
Intervention: Exoskeletal-assisted walking (EAW) alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exoskeletal-assisted walking plus transcutaneous spinal cord stimulation (EAW+tSCS)
Number of subjects: 16
Study: 39289029

Group type: EXPERIMENTAL
Intervention: E6742 100 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: E6742 200 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 39289057

Group type: EXPERIMENTAL
Intervention: Esomeprazole/magnesium hydroxide 40/350 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Enteric-coated esomeprazole 40 mg
Number of subjects: 49
Study: 39289059

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bendamustine-rituximab (R-bendamustine)
Number of subjects: 0
Study: 39289093

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing arm (n=34)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Skin care arm (n=34)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control arm (n=34)
Number of subjects: 102
Study: 39289145

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg daily)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 39289218

Group type: EXPERIMENTAL
Intervention: Hugo™ RAS system
Number of subjects: 40
Study: 39289373

Group type: EXPERIMENTAL
Intervention: Adaptive deep brain stimulation (aDBS)
Number of subjects: 68
Study: 39289377

Group type: EXPERIMENTAL
Intervention: 20 mcg single dose of H10ssF vaccine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 60 mcg two doses of H10ssF vaccine
Number of subjects: 25
Study: 39289471

Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise focusing on quadriceps muscles for 3 months
Number of subjects: 7
Study: 39289473

Group type: EXPERIMENTAL
Intervention: Postocclusive reactive hyperemia (PORH)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 64
Study: 39289610

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in survivors (30 days)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in survivors (180 days)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in patients aged < 65 years (30 days)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in patients aged < 65 years (180 days)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: ROC AUC for NLR in patients aged < 65 years (30 days)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: ROC AUC for NLR in patients aged < 65 years (180 days)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression for NLR
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression for age
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Survival analysis for 180 days mortality
Number of subjects: 851
Study: 39289646

Group type: EXPERIMENTAL
Intervention: Parenting intervention arm
Number of subjects: 640

Group type: COMPARATOR
Intervention: Waitlist control arm
Number of subjects: 640
Study: 39289685

Group type: EXPERIMENTAL
Intervention: Oral synbiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39289739

Group type: EXPERIMENTAL
Intervention: fSCIG 10%
Number of subjects: 42
Study: 39289750

Group type: EXPERIMENTAL
Intervention: Interactive decision support tool (DST)
Number of subjects: 132
Study: 39289760

Group type: EXPERIMENTAL
Intervention: Intraoperative pneumatic tourniquet application
Number of subjects: 34

Group type: COMPARATOR
Intervention: No tourniquet application
Number of subjects: 34
Study: 39289825

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TU)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (Training)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Combination of testosterone therapy (TU) and progressive resistance training (Combo)
Number of subjects: 148

Group type: COMPARATOR
Intervention: No intervention (Controls)
Number of subjects: 148
Study: 39290050

Group type: EXPERIMENTAL
Intervention: Remote electrical neuromodulation (REN)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intravenous interventions (typical care)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: REN
Number of subjects: 22

Group type: COMPARATOR
Intervention: Typical care (intravenous metoclopramide and ketorolac)
Number of subjects: 22
Study: 39290059

Group type: EXPERIMENTAL
Intervention: Strongest Families Smart Website (SFSW)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Education Control (EC)
Number of subjects: 464
Study: 39290122

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow derived mesenchymal stromal cells (BM-MSCs) transplantation after lunate core decompression
Number of subjects: 3
Study: 39290129

Group type: EXPERIMENTAL
Intervention: Agent PCB
Number of subjects: 262

Group type: COMPARATOR
Intervention: SeQuent Please PCB
Number of subjects: 262
Study: 39290519

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for smoking cessation, n = 30, implemented in group-based sessions over an eight-week period
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group, n = 30, including a brief psychoeducation advice about smoking cessation
Number of subjects: 60
Study: 39290639

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 50 mg/kg with TBI 2 Gy, ATG and fludarabine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 100 mg/kg with TBI 2 Gy, ATG and fludarabine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 0 mg/kg with TBI 2 Gy, ATG and fludarabine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 150 mg/kg with TBI 2 Gy, ATG and fludarabine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients aged ≥50 years
Number of subjects: 96
Study: 39290680

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) with the MitraClip device plus guideline-directed medical therapy (GDMT)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 614
Study: 39290817

Group type: EXPERIMENTAL
Intervention: Mean transvalvular pressure gradient to effective orifice area ratio (MG/EOA)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: MG/EOA ratio
Number of subjects: 188
Study: 39290861

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 7752

Group type: COMPARATOR
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 7752
Study: 39290981

Group type: EXPERIMENTAL
Intervention: GSK3326595 400 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GSK3326595 300 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GSK3326595
Number of subjects: 30
Study: 39291052

Group type: EXPERIMENTAL
Intervention: Anxiolytic drugs (alprazolam, bromazepam, lorazepam, meprobamate, midazolam, oxazepam)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 8
Study: 39291193

Group type: EXPERIMENTAL
Intervention: Transcriptome-driven approach utilizing renal biopsies from AL amyloidosis participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite scarring injury and amyloid score (AS) assigned to each biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expression data compared to healthy living donors and focal segmental glomerulosclerosis (FSGS) profiles
Number of subjects: 0
Study: 39291206

Group type: EXPERIMENTAL
Intervention: Felzartamab
Number of subjects: 31
Study: 39291212

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 60
Study: 39291249

Group type: EXPERIMENTAL
Intervention: Unguided modular online intervention (8 modules, ~20 min each)
Number of subjects: 1811

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Unguided modular online intervention
Number of subjects: 1811
Study: 39291303

Group type: EXPERIMENTAL
Intervention: Omalizumab-assisted multi-food oral immunotherapy (mOIT)
Number of subjects: 0
Study: 39291332

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) for Breast Cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39291473

Group type: EXPERIMENTAL
Intervention: BE FAST
Number of subjects: 174

Group type: COMPARATOR
Intervention: FAST
Number of subjects: 174
Study: 39291483

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 186
Study: 39291487

Group type: EXPERIMENTAL
Intervention: 12-week rehabilitation intervention
Number of subjects: 349

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 349
Study: 39291498

Group type: EXPERIMENTAL
Intervention: Training group (MFS-T)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (MFS-C)
Number of subjects: 70
Study: 39291502

Group type: EXPERIMENTAL
Intervention: Guideline-directed optimal medical therapy (receiving angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and statins)
Number of subjects: 89462

Group type: COMPARATOR
Intervention: SMuRFs (standard modifiable cardiovascular risk factors)
Number of subjects: 89462

Group type: EXPERIMENTAL
Intervention: SMuRF-less patients
Number of subjects: 89462
Study: 39291635

Group type: EXPERIMENTAL
Intervention: Estimated aortic pulse wave velocity (aPWV)
Number of subjects: 1046
Study: 39291867

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Model 1 (including 5 pretreatment predictors)
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Model 2 (including 2 treatment-related predictors)
Number of subjects: 1676
Study: 39291967

Group type: EXPERIMENTAL
Intervention: High-dose glucagon
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no glucagon)
Number of subjects: 28
Study: 39292112

Group type: COMPARATOR
Intervention: Manual Therapy (MT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Electro-massage (ES) combined with Manual Therapy (MT)
Number of subjects: 46
Study: 39292188

Group type: EXPERIMENTAL
Intervention: Stool DNA-based SDC2 methylation test
Number of subjects: 1124
Study: 39292351

Group type: EXPERIMENTAL
Intervention: StrataXRT
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard of care and Mepitel Film (MF)
Number of subjects: 43
Study: 39292433

Group type: EXPERIMENTAL
Intervention: Donanemab (13 doses over 1 year)
Number of subjects: 0
Study: 39292443

Group type: EXPERIMENTAL
Intervention: Roflumilast cream, 0.15%
Number of subjects: 1337

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 1337
Study: 39292452

Group type: EXPERIMENTAL
Intervention: YAWNS-1 (Sleepwell package)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: YAWNS-2 (updated booklets)
Number of subjects: 565

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: YAWNS-1
Number of subjects: 565
Study: 39292459

Group type: EXPERIMENTAL
Intervention: Balanced crystalloids (via EHR alert)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Usual care (normal saline)
Number of subjects: 6
Study: 39292927

Group type: EXPERIMENTAL
Intervention: Axatilimab 0.3 mg/kg every 2 weeks
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Axatilimab 1 mg/kg every 2 weeks
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Axatilimab 3 mg/kg every 4 weeks
Number of subjects: 241
Study: 39292928

Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg daily for 24 weeks)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 24 weeks)
Number of subjects: 144
Study: 39292975

Group type: EXPERIMENTAL
Intervention: Atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 39292994

Group type: EXPERIMENTAL
Intervention: Early maturing girls
Number of subjects: 81

Group type: COMPARATOR
Intervention: Late maturing girls
Number of subjects: 81
Study: 39293025

Group type: EXPERIMENTAL
Intervention: Quantitative immunoprecipitation mass spectrometry (QIP-MS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Next-generation flow (NGF) cytometry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QIP-MS
Number of subjects: 0

Group type: COMPARATOR
Intervention: NGF and MS
Number of subjects: 0
Study: 39293050

Group type: EXPERIMENTAL
Intervention: Gaming-based dementia educational program (90 minutes duration)
Number of subjects: 0
Study: 39293082

Group type: EXPERIMENTAL
Intervention: UM171 during LVV transduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cells transduced with UM171
Number of subjects: 0
Study: 39293083

Group type: EXPERIMENTAL
Intervention: M+R (magrolimab plus rituximab)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: M+R-GemOx (magrolimab plus rituximab plus gemcitabine-oxaliplatin)
Number of subjects: 132
Study: 39293201

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Stress Ball
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 39293214

Group type: EXPERIMENTAL
Intervention: vYF vaccine (4, 5 or 6 Log CCID)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: vYF vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: YF-VAX vaccine
Number of subjects: 100
Study: 39293461

Group type: EXPERIMENTAL
Intervention: Lutetium-177
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 130
Study: 39293462

Group type: EXPERIMENTAL
Intervention: Open-label, intravenous treatment (specific treatment not mentioned)
Number of subjects: 468
Study: 39293494

Group type: EXPERIMENTAL
Intervention: One-step increase in temperature (34-37°C)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: No temperature increase (started and remained at 37°C)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Two-step increase (31 to 34 to 37°C)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Overall comfort across all study arms
Number of subjects: 21
Study: 39293515

Group type: EXPERIMENTAL
Intervention: BMS-986365 (CC-94676) at doses of 400-900 mg twice daily (n = 60)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BMS-986365 (CC-94676)
Number of subjects: 95
Study: 39293778

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (RT) plus bone-loading exercises and placebo capsules
Number of subjects: 308

Group type: COMPARATOR
Intervention: No RT and placebo capsules
Number of subjects: 308
Study: 39293786

Group type: EXPERIMENTAL
Intervention: Coronary magnetic resonance angiography (CMRA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 201
Study: 39294027

Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 3840

Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 3840
Study: 39294033

Group type: EXPERIMENTAL
Intervention: Presence of carotid plaque (CP)
Number of subjects: 2419
Study: 39294149

Group type: EXPERIMENTAL
Intervention: BWC0977 (Novel Bacterial Topoisomerase Inhibitor)
Number of subjects: 0
Study: 39294181

Group type: EXPERIMENTAL
Intervention: CytoSorb (CS) application
Number of subjects: 16
Study: 39294392

Group type: EXPERIMENTAL
Intervention: Physicians' evaluations of SD-OCT scans
Number of subjects: 133

Group type: COMPARATOR
Intervention: Reading centres (RCs) evaluations of SD-OCT scans
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Combined ME cohort evaluations
Number of subjects: 133

Group type: COMPARATOR
Intervention: Visits with RC-detected foveal IRF and/or SRF
Number of subjects: 133

Group type: COMPARATOR
Intervention: Visits with foveal fluid
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Overall BCVA outcomes
Number of subjects: 133
Study: 39294452

Group type: EXPERIMENTAL
Intervention: Polypharmacy (≥8 medications)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (≥1 PIM per STOPP)
Number of subjects: 616
Study: 39294471

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) with a translocator protein radioligand
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional magnetic resonance imaging (MRI)
Number of subjects: 25
Study: 39294486

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 35 cycles
Number of subjects: 7
Study: 39294522

Group type: EXPERIMENTAL
Intervention: Atomoxetine (10 or 18 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 39294600

Group type: EXPERIMENTAL
Intervention: 3D CT angiography
Number of subjects: 69

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 69
Study: 39294617

Group type: EXPERIMENTAL
Intervention: Admission SBP ≤ 120 mmHg
Number of subjects: 3809

Group type: EXPERIMENTAL
Intervention: Admission SBP > 120 mmHg
Number of subjects: 3809

Group type: EXPERIMENTAL
Intervention: Admission SBP 121-150 mmHg
Number of subjects: 3809

Group type: EXPERIMENTAL
Intervention: SBP ≤ 120 mmHg in Killip class I-II
Number of subjects: 3809

Group type: EXPERIMENTAL
Intervention: Admission SBP above 120 mmHg
Number of subjects: 3809
Study: 39294797

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave (ESW) therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave (ESW) combined with PRP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 39294818

Group type: EXPERIMENTAL
Intervention: Remifentanil (REM)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX)
Number of subjects: 179
Study: 39295091

Group type: EXPERIMENTAL
Intervention: Stroke-side rowers
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-rowing controls
Number of subjects: 64

Group type: COMPARATOR
Intervention: Scull rowers
Number of subjects: 64
Study: 39295627

Group type: EXPERIMENTAL
Intervention: Severe stenosis (CSA values)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Moderate stenosis (CSA values)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Average CSA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cervical Radiculopathy Impact Scale
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L General Quality of Life Scale
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Severity of cervical stenosis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Neck and arm pain, numbness, disability, and quality of life
Number of subjects: 64
Study: 39296351

Group type: EXPERIMENTAL
Intervention: Low, medium, and high-intensity aquatic physiotherapy protocols
Number of subjects: 15

Group type: COMPARATOR
Intervention: Reference group (same aquatic physiotherapy protocols)
Number of subjects: 15
Study: 39296821

Group type: EXPERIMENTAL
Intervention: Intermediate-to-fast AS progression rate (median change in peak aortic jet velocity ≥0.11 m/s/year)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Functional status decline during follow-up
Number of subjects: 244
Study: 39296829

Group type: EXPERIMENTAL
Intervention: Neurofeedback-Assisted Mindfulness Training Program (NAMTP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study: 39296832

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) at age 5.5 years
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Reallocating 30 minutes from MVPA to sleep
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Organized PA/sports, outdoor play, and reading books
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Indoor play and screen-viewing
Number of subjects: 432
Study: 39296855

Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 39296979

Group type: EXPERIMENTAL
Intervention: Prolgolimab 250 mg Q3W
Number of subjects: 114

Group type: COMPARATOR
Intervention: Prolgolimab 1 mg/kg Q2W (historical control)
Number of subjects: 114
Study: 39297052

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 7 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 10 mg/kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 39297416

Group type: EXPERIMENTAL
Intervention: Local anesthesia with distal median nerve block
Number of subjects: 118

Group type: COMPARATOR
Intervention: Local anesthesia alone
Number of subjects: 118
Study: 39297486

Group type: EXPERIMENTAL
Intervention: High-EMST
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-EMST
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: EMST
Number of subjects: 31
Study: 39297691

Group type: EXPERIMENTAL
Intervention: PanBio indirect dengue virus immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Higher IgG cut point
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Plaque reduction neutralization tests (PRNTs)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Plaque reduction neutralization tests (PRNTs) with Zika, Japanese encephalitis, and West Nile viruses
Number of subjects: 770